Skip to main content
Dechra Pharmaceuticals PLC logo

Dechra Pharmaceuticals PLC — Investor Relations & Filings

Ticker · DPH ISIN · US2434351043 LEI · 213800J4UVB5OWG8VX82 IL Manufacturing
Open in API
Filings indexed 1,018 across all filing types
Latest filing 2021-02-25 Major Shareholding Noti…
Country GB United Kingdom
Listing IL DPH

About Dechra Pharmaceuticals PLC

https://www.dechra.com/

Dechra Pharmaceuticals PLC is a global specialist business focused on veterinary pharmaceuticals and related products. The company's expertise encompasses the development, manufacture, marketing, and sale of high-quality veterinary medicines. Its product portfolio includes both novel and differentiated generic pharmaceuticals, with a significant focus on products for companion animals. Dechra provides solutions and support to veterinary professionals worldwide to improve animal health and welfare.

Recent filings

Filing Released Lang Actions
Holding(s) in Company
Major Shareholding Notification Classification · 100% confidence The document is explicitly identified by the 'RNS Number' and contains the header 'TR-1: Standard form for notification of major holdings'. This form is used to report changes in major shareholdings, which directly corresponds to the definition of a Major Shareholding Notification. The content details the acquisition/disposal of voting rights by BlackRock, Inc., crossing a threshold, and provides specific percentage changes. This aligns perfectly with the 'Major Shareholding Notification' category (MRQ). Although it is distributed via RNS, the specific content dictates the classification over the general RNS fallback.
2021-02-25 English
Dechra Pharmaceuticals PLC - 2021 Half Yearly Report
Earnings Release Classification · 100% confidence The document is explicitly titled 'Half-Yearly Financial Report 2021 for the six months ended 31 December 2020'. It contains detailed financial summaries, operational reviews for specific segments (European Pharmaceuticals, North American Pharmaceuticals), product category performance, acquisition updates, and management commentary covering a period shorter than a full year (six months). This content structure perfectly matches the definition of a comprehensive financial report for a period shorter than a year, which corresponds to the Interim / Quarterly Report category. H1 2021
2021-02-22 English
Half-yearly Report six months to 31 December 2020
Interim / Quarterly Report Classification · 100% confidence The document is a 'Half-Yearly Financial Report' for Dechra Pharmaceuticals PLC for the six months ended 31 December 2020. It contains comprehensive financial statements, operational reviews, and financial analysis. It is not an announcement of a report, but the report itself, and it covers a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. H1 2021
2021-02-22 English
Exclusive Licensing Agreement & Share Acquisition
Regulatory Filings Classification · 100% confidence The document starts with an 'RNS Number' and is dated 08 February 2021. It announces a significant corporate transaction: securing exclusive licensing rights and acquiring a minority stake in another company (Medical Ethics Pty Ltd/Animal Ethics Pty Ltd) for a specific consideration. This type of announcement, detailing strategic business development, licensing, and share acquisition, is a material event requiring immediate public disclosure. Since it is a general regulatory announcement distributed via RNS (London Stock Exchange's news service) and concerns a strategic business development rather than a periodic financial report (10-K, IR, ER) or a specific shareholder vote/director dealing, it fits best under the general 'Regulatory Filings' category, which serves as a fallback for material, non-standard announcements. It is not a specific M&A takeover bid (TAR) but a licensing/minority investment deal. Given the source (RNS) and the nature of the announcement (material corporate action), RNS is the most appropriate classification.
2021-02-08 English
Total Voting Rights
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a notification released via RNS (Regulatory News Service) with the RNS Number 6001N. The content explicitly states the 'Total Voting Rights' as of the announcement date (01 February 2021), referencing compliance with DTR 5.6.1R (Disclosure and Transparency Rules). This type of filing, which communicates a change in the total number of shares with voting rights, is a mandatory regulatory disclosure. While it relates to share capital, it is not a formal share issue announcement (SHA) or a transaction in own shares (POS). It is a specific regulatory update concerning shareholder voting denominator information. Since it is a general regulatory announcement provided through the RNS system and doesn't fit perfectly into the other specific categories like DIV, DIRS, or CAP, the most appropriate classification is the general regulatory filing category, RNS, especially given the RNS header and footer information.
2021-02-01 English
Holding(s) in Company
Major Shareholding Notification Classification · 99% confidence The document is explicitly titled 'TR-1: Standard form for notification of major holdings' and contains an RNS Number (4327N) from Dechra Pharmaceuticals PLC, dated 29 January 2021. It details changes in voting rights held by BlackRock, Inc., crossing a threshold (5.04% direct voting rights). This type of filing, which reports changes in significant share ownership, directly corresponds to the definition of Major Shareholding Notification (MRQ). Although it is an RNS announcement, the content is highly specific to a major holding change, making MRQ the most accurate classification over the general RNS fallback.
2021-01-29 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.